☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
UCB
UCB Reports the Commercial Availability of Rystiggo (rozanolixizumab-noli) for Adult Patients with Generalized Myasthenia Gravis i...
July 21, 2023
UCB’s Rystiggo (rozanolixizumab) Receives the US FDA’s Approval for the Treatment of Adults with Generalized Myasthenia Gravis
June 27, 2023
UCB’s Bimzelx (bimekizumab) Receives EC’s Marketing Authorisation for the Treatment of Psoriatic Arthritis and Axial Spondyloarthr...
June 7, 2023
UCB Entered into a Research Collaboration with Ariceum Therapeutics to Discover New Modalities for Immune-related Diseases and Can...
May 11, 2023
UCB Published P-III Studies (MycarinG) & (RAISE) of Rozanolixizumab and Zilucoplan for Generalized Myasthenia Gravis in The Lancet...
April 13, 2023
UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa
March 20, 2023
Load more...
Back to Home